Association between early PSA increase and clinical outcome in patients treated with enzalutamide for metastatic castration resistant prostate cancer.
Authors
Conteduca, VCrabb, S
Scarpi, E
Hanna, C
Maines, F
Joyce, Helen
Fabbri, P
Derosa, L
Massari, F
Lolli, C
Zarif,S
Jones, R
Caffo, O
Elliott, Tony
De Giorgi, U
Affiliation
Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.) IRCCS, Via Piero Maroncelli 40, 47014, Meldola, FC, ItalyIssue Date
2016-03-28
Metadata
Show full item recordAbstract
Prostate-specific antigen (PSA) decline by 50 % from the baseline to 12 weeks (PSA50w12) is currently used to predict response to treatment and clinical outcome of patients with metastatic castration-resistant prostate cancer (mCRPC). We evaluated the association between PSA changes at 4 weeks and clinical outcome.Citation
Association Between Early PSA Increase and Clinical Outcome in Patients Treated with Enzalutamide for Metastatic Castration Resistant Prostate Cancer. 2016: Mol Diagn TherJournal
Molecular Diagnosis & TherapyDOI
10.1007/s40291-016-0196-1PubMed ID
27020582Type
ArticleLanguage
enISSN
1179-2000ae974a485f413a2113503eed53cd6c53
10.1007/s40291-016-0196-1
Scopus Count
Collections
Related articles
- Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel.
- Authors: Armstrong AJ, Saad F, Phung D, Dmuchowski C, Shore ND, Fizazi K, Hirmand M, Forer D, Scher HI, Bono J
- Issue date: 2017 Jun 15
- Prognostic Association of Prostate-specific Antigen Decline with Clinical Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Treated with Enzalutamide in a Randomized Clinical Trial.
- Authors: Armstrong AJ, Lin P, Higano CS, Iversen P, Sternberg CN, Tombal B, Phung D, Parli T, Krivoshik A, Beer TM
- Issue date: 2019 Nov
- An exploratory retrospective multicenter study of prognostic factors in mCRPC patients undergoing enzalutamide treatment: Focus on early PSA decline and kinetics at time of progression.
- Authors: Miyazawa Y, Sekine Y, Shimizu N, Takezawa Y, Nakamura T, Miyao T, Nakayama H, Kurihara S, Syuto T, Nomura M, Koike H, Matsui H, Shibata Y, Suzuki K
- Issue date: 2019 Sep
- Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
- Authors: Hussain M, Fizazi K, Saad F, Rathenborg P, Shore N, Ferreira U, Ivashchenko P, Demirhan E, Modelska K, Phung D, Krivoshik A, Sternberg CN
- Issue date: 2018 Jun 28
- Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial.
- Authors: Saad F, de Bono J, Shore N, Fizazi K, Loriot Y, Hirmand M, Franks B, Haas GP, Scher HI
- Issue date: 2015 Feb